All Type of News
M&As, restructuring to sweep pharmaceutical industry
The government’s tougher action against illegal rebates in the local pharmaceutical industry is making it harder for small- and medium-sized firms to do business.
Analysts expect a large number of mergers and acqu...
KFDA seeks to integrate testing agency related regulations
The Korea Food and Drug Administration said on July 31 it will enact a bill to integrate four rules concerning designation of testing organizations eligible for analysis of all medical goods, drugs, food and cosmetic ...
Number of medical institutions up 1,673
The Health Insurance Review and Assessment Service (HIRAS) said that Korea has a total of 79,456 medical institutions as of August 1, this year, up 1,673 from 2008.
The HIRAS data show that there are 44 specialized...
Individual warfarin dose with generic information
The Korea Food and Drug Administration a label update on warfarin on July 31, saying the label change marked the first time KFDA has employed gene-specific information in labeling for a major drug.
Warfarin is a co...
Steps sought to activate domestic biosimilar development
The establishment of a regulatory pathway for biosimilars will be the first step in creating a market pathway for biosimilars, according to the Korea Food and Drug Administration.
In an information session on July ...
Domestic pharmaceutical industry likely to lose momentum over rebate ban
Korean firms’ generic drugs are expected to lose steam once the government cracks down on pharmaceutical firms offering rebates starting August.
Experts said domestic manufacturers can no longer expect to live off ...
Pharmaceutical industry vows to root out illicit practices
The Korea Pharmaceutical Manufacturers Association pledged to improve unethical practices in the pharmaceutical industry at a special board of directors meeting held on July 30.
50 members of the KPMA discussed cou...
Korea paints too rosy picture for biosimilars development
The government is now being criticized for only drawing a “hollow’’ picture on the biosimilars sector, since there are many key challenges and huddles.
Critics and industry sources said the government’s optimistic ...
Rebate ban corners small drugmakers
A majority of small pharmaceutical firms are now agonizing over falling sales of their prescription drugs the government will be allowed to forcibly lower drug prices by up to 20 percent if their producers are found t...
Race for drug top supremacy heats up
Industry watchers claim that the race for the top in the domestic pharmaceutical market is likely to continue to heat up this year among Korea’s top three pharmaceutical firms – Dong-A, Yuhan and Hanmi.
"Inspired b...
